In another cohort study, the odds ratio (OR) for ILD in the TNF inhibitor group was insignificant when compared with that in csDMARD users (OR = 1.03, 95% CI 0.51–2.07) [119]. This evidence concerns the gene TNF and interstitial lung disease.